[Management of bone lesions in multiple myeloma]
Hiroyuki Hata1, Hiroaki Mitsuya
1Dept. of Hematology, Kumamoto University Hospital.
Abstract:
Bone destruction is a key feature of multiple myeloma, which causes significant impairment of patients' activity. Some of the mechanisms regulating bone destruction have recently been clarified, and the management of bone diseases in myeloma patients has made considerable progress. Moreover,imaging techniques for screening bone lesions have been developed, such as PET scan or (99m)Tc scan, other than regular X-ray analysis. We describe here strategies for the management of bone disease in myeloma, e.g., ( I ) effective chemotherapy against myeloma cells, (II) decrease of osteoclasts by bisphosphonates, (III) surgical treatment of damaged bone, (IV) irradiation to lytic bone lesion and (V) other forms of supportive care. All of these approaches should be effectively integrated to improve the quality of life of myeloma patients.
Insights
Multiple myeloma often causes bone destruction, impairing patient activity. Integrated management strategies, including chemotherapy and bisphosphonates, improve quality of life for myeloma patients with bone disease.
Area of Science:
- Oncology
- Bone Biology
- Medical Imaging
Background:
- Multiple myeloma is characterized by significant bone destruction, leading to impaired patient mobility and quality of life.
- Recent advancements have elucidated mechanisms underlying myeloma-induced bone loss.
- Improved diagnostic tools, including PET and (99m)Tc scans alongside X-rays, aid in early detection of bone lesions.
Purpose of the Study:
- To outline comprehensive strategies for managing bone disease in multiple myeloma patients.
- To highlight the integration of various therapeutic and supportive approaches.
- To emphasize the goal of improving patients' quality of life.
Main Methods:
- Review of current therapeutic strategies for myeloma bone disease.
- Discussion of chemotherapy for myeloma cell control.
- Explanation of osteoclast inhibition using bisphosphonates.
- Consideration of surgical interventions and radiation therapy for bone lesions.
- Inclusion of supportive care measures.
Main Results:
- Effective chemotherapy targets myeloma cells, a primary driver of bone destruction.
- Bisphosphonates significantly decrease osteoclast activity, mitigating bone resorption.
- Surgical and radiological interventions address specific lytic bone lesions.
- Integrated management encompassing chemotherapy, bisphosphonates, surgery, irradiation, and supportive care offers a multi-faceted approach.
Conclusions:
- A multidisciplinary and integrated approach is crucial for optimal management of bone disease in multiple myeloma.
- Combining systemic therapies, bone-modifying agents, local treatments, and supportive care enhances patient outcomes.
- Effective management of bone complications significantly improves the quality of life for individuals with multiple myeloma.